NASDAQ:ALDR - Alder Biopharmaceuticals, Inc.
$14.21
 $0.23
+1.65%
2:25PM EDT
2019-02-15
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ALDR     avg for
industry  
  avg for
sector  
42 stocks weight:  48. 37   0. 00   0. 00  
42 stocks rank:  2. 78 K 1. 86 K 1. 09 K
# analyst opinions:  16. 00   14. 92   14. 43  
mean recommendation:  2. 30   1. 91   1. 93  

quick ratio:  14. 87   5. 37   1. 81  
current ratio:  15. 34   5. 69   2. 19  

target price low:  9. 00   88. 97   117. 82  
target price avg:  22. 00   115. 19   141. 96  
target price high:  36. 00   143. 40   163. 16  
1-yr high:  19. 90   124. 30   142. 77  
last close:  13. 98   101. 85   127. 84  
50-day avg:  12. 02   98. 27   122. 46  
200-day avg:  15. 10   99. 72   122. 70  
1-yr low:  9. 80   78. 19   100. 16  
volume:  278. 77 K 2. 38 M 4. 64 M
50-day avg volume:  906. 51 K 3. 31 M 4. 94 M
200-day avg volume:  879. 02 K 3. 23 M 4. 28 M

1-day return:  0. 43 % 0. 22 % 0. 48 %
this week return:  1. 08 % 1. 77 % 2. 01 %
12-wk return:  5. 59 % 6. 56 % 3. 33 %
52-wk return:  3. 31 % -2. 23 % 14. 35 %

enterprise value (EV):  772. 68 M 55. 17 B 104. 51 B
market cap:  955. 21 M 49. 01 B 96. 46 B
EBITDA:  -236. 34 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -3. 27   -91. 79   2. 29  
enterprise/revenue (EV/R):  825. 52   29. 84   23. 39  
total revenue:  936. 00 K 11. 28 B 40. 22 B
total debt:  179. 04 M 13. 73 B 16. 57 B
debt/equity:  62. 79   258. 01   110. 73  
net income (common):  -304. 82 M 2. 37 B 3. 58 B

shares outstanding:  68. 33 M 607. 99 M 1. 22 B
shares:  51. 94 M 605. 53 M 1. 15 B
shares short:  12. 49 M 11. 62 M 12. 55 M
shares short prior month:  10. 98 M 11. 95 M 13. 44 M
short ratio:  11. 09   4. 82   3. 10  
short % of float:  21. 63 % 6. 19 % 2. 82 %
total cash/share:  6. 62   12. 02   11. 46  
total cash:  452. 41 M 7. 41 B 7. 37 B
free cash flow:  -126. 73 M 95. 99 M 2. 04 B
operating cash flow:  -233. 53 M 164. 74 M 3. 04 B

book value:  2. 70   14. 43   28. 26  
price/book:  5. 19   -1. 57   -2. 97  
gross profits:  -188. 68 M 8. 28 B 18. 09 B
operating margins:  -25560. 47 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  17. 47 % --- ---
1-yr mean volatility:  0. 06 % 0. 01 % 0. 06 %

1-yr EPS:  -4. 48   3. 03   4. 09  
forward EPS:  -3. 36   4. 33   6. 99  
P/E:  -3. 12   6. 11   26. 91  
forward P/E:  -4. 12   8. 38   10. 48  
PE/G:  0. 16   0. 37   5. 61  
growth:  -19. 60 % 683. 72 % 104. 79 %
earnings high:  -0. 81   1. 27   1. 66  
earnings avg:  -0. 94   1. 01   1. 53  
earnings low:  -1. 36   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -34. 65 % -3. 27 % 3. 81 %
return on equity:  -88. 42 % 107. 48 % 27. 82 %
revenue/share:  0. 01   14. 68   59. 83  

beta (1yr vs S&P500):  1. 18   1. 21   0. 93  
sharpe (1yr):  0. 25   0. 06   0. 98  

held % insiders:  6. 33 % 6. 46 % 3. 21 %
held % institutions:  111. 27 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : ALDR
.        + 0 =             0 :: INITIAL WEIGHT
.  + 226.083 =       226.083 :: inverse volume-to-price addition
.  + 227.372 =       453.455 :: spline projection addition
.  - 136.682 =       316.773 :: poor performance penalty
.    x 1.051 =       332.969 :: one-year gains+dividend factor
.    x 7.328 =      2440.075 :: 13 weeks' performance factor
.    x 1.492 =      3641.785 :: industry recommendation factor
.    x 1.502 =      5468.716 :: symbol recommendation factor
.    x 5.357 =     29298.639 :: EV/R factor
.    x 0.997 =     29197.117 :: return on assets factor
.    x 0.991 =     28938.956 :: return on equity factor
.    x 2.694 =     77964.267 :: current ratio factor
.    x 1.035 =     80725.109 :: quick ratio factor
.    x 1.044 =     84286.112 :: short ratio factor
.     x 2.07 =    174514.123 :: price-to-book factor
.    x 1.115 =    194594.506 :: debt-to-equity factor
.    x 1.154 =    224651.662 :: 5-day avg > 50-day avg
.    x 2.157 =     484593.97 :: P/E weight
.    x 1.584 =    767356.804 :: PE/G factor
.    x 1.637 =   1256325.004 :: beta factor
.    x 0.247 =     310816.43 :: sharpe factor
.     x 0.94 =    292265.527 :: target low factor
.    x 1.252 =     366054.24 :: target mean factor
.    x 1.126 =    411995.248 :: target high factor
.    x 1.066 =    439027.412 :: industry 12-weeks return
.    x 0.999 =     438773.77 :: overall "drift" factor
.    x 0.825 =    362116.123 :: largest single-day jump factor
.    x 0.313 =    113161.288 :: low price factor
.      x 1.0 =    113168.884 :: factor hist industry gain for week 06
.   cubeRoot =         48.37 :: reduced for readability
.                      48.37 :: FINAL WEIGHT for NASDAQ:ALDR


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org